© 2001 by Oxford University Press
Journal of the National Cancer Institute, Vol. 93, No. 19, 1479-1483,
October 3, 2001
© 2001 Oxford University Press
REPORT |
Familial Multiple Myeloma: a Family Study and Review of the Literature
Affiliations of authors: H. T. Lynch, B. Quinn-Laquer, Department of Preventive Medicine, Creighton University School of Medicine, Omaha, NE; W. G. Sanger (Human Genetics Laboratory), S. Pirruccello, D. D. Weisenburger (Department of Pathology and Microbiology), University of Nebraska Medical Center, Omaha.
Correspondence to: Henry T. Lynch, M.D., Department of Preventive Medicine, Creighton University School of Medicine, 2500 California Plaza, Omaha, NE 68178 (e-mail: htlynch{at}creighton.edu).
Background: The etiology of multiple myeloma (MM) remains obscure, although reports of familial clustering have implicated both a host susceptibility factor and environmental effects. Here we describe the medical histories of members of a family prone to MM. Methods: We developed a pedigree for an MM-prone family by using information obtained from a questionnaire. Protein immunoelectrophoresis of serum and urine from the proband and from 19 family members was performed to detect monoclonal immunoproteins. Peripheral blood obtained from the proband and from five relatives was subjected to standard cytogenetic studies to detect constitutional chromosomal abnormalities. Multifluor-fluorescence in situ hybridization (M-FISH) and standard FISH studies were performed on peripheral blood from the proband and from two other affected living relatives to determine their karyotypes and to detect clonal chromosomal abnormalities frequently seen in patients with MM. Results: Within this family, a sibship of seven included three individuals (including the proband) with histologically verified MM and two individuals with a monoclonal gammopathy of unknown significance (MGUS), as determined by immunoelectrophoresis of serum and urine. This family also had members with acute lymphocytic leukemia, malignant melanoma, and prostate cancer. In the family members tested, we detected no constitutional chromosomal abnormality. None of the three individuals analyzed by FISH had a deletion of the retinoblastoma (Rb-1) locus, which is frequently deleted in patients with MM, and only one (the proband) had a translocation involving chromosomes 11 and 14, a clonal abnormality commonly seen in MM. Conclusion: The study of familial MM may provide insights into the pathogenesis and, ultimately, the control and prevention of MM and related disorders.
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  H. T. Lynch and S. D. Thome Familial multiple myeloma Blood, July 23, 2009; 114(4): 749 - 750. [Full Text] [PDF]
|
|
|
|
|
|
O. Landgren, S. Y. Kristinsson, L. R. Goldin, N. E. Caporaso, C. Blimark, U.-H. Mellqvist, A. Wahlin, M. Bjorkholm, and I. Turesson Risk of plasma cell and lymphoproliferative disorders among 14621 first-degree relatives of 4458 patients with monoclonal gammopathy of undetermined significance in Sweden Blood, July 23, 2009; 114(4): 791 - 795. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. T. Lynch, K. Ferrara, B. Barlogie, E. A. Coleman, J. F. Lynch, D. Weisenburger, W. Sanger, P. Watson, H. Nipper, V. Witt, et al. Familial Myeloma N. Engl. J. Med., July 10, 2008; 359(2): 152 - 157. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 P. L. Bergsagel and W. M. Kuehl Molecular Pathogenesis and a Consequent Classification of Multiple Myeloma J. Clin. Oncol., September 10, 2005; 23(26): 6333 - 6338. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. T. Lynch, P. Watson, S. Tarantolo, P. H. Wiernik, B. Quinn-Laquer, K. Isgur Bergsagel, L. Huiart, O.I. Olopade, H. Sobol, W. Sanger, et al. Phenotypic Heterogeneity in Multiple Myeloma Families J. Clin. Oncol., February 1, 2005; 23(4): 685 - 693. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
T. Hideshima, P. L. Bergsagel, W. M. Kuehl, and K. C. Anderson Advances in biology of multiple myeloma: clinical applications Blood, August 1, 2004; 104(3): 607 - 618. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Cuendet, K. Christov, D. D. Lantvit, Y. Deng, S. Hedayat, L. Helson, J. D. McChesney, and J. M. Pezzuto Multiple Myeloma Regression Mediated by Bruceantin Clin. Cancer Res., February 1, 2004; 10(3): 1170 - 1179. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Barille-Nion, B. Barlogie, R. Bataille, P. L. Bergsagel, J. Epstein, R. G. Fenton, J. Jacobson, W. M. Kuehl, J. Shaughnessy, and G. Tricot Advances in Biology and Therapy of Multiple Myeloma Hematology, January 1, 2003; 2003(1): 248 - 278. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. Hemminki and K. Czene Attributable Risks of Familial Cancer from the Family-Cancer Database Cancer Epidemiol. Biomarkers Prev., December 1, 2002; 11(12): 1638 - 1644. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Sobol, N. Vey, R. Sauvan, N. Philip, T. Noguchi, and F. Eisinger Re: Familial Multiple Myeloma: a Family Study and Review of the Literature J Natl Cancer Inst, March 20, 2002; 94(6): 461 - 462. [Full Text] [PDF]
|
|
|
|
|
|
K. Hemminki Re: Familial Multiple Myeloma: a Family Study and Review of the Literature J Natl Cancer Inst, March 20, 2002; 94(6): 462 - 463. [Full Text] [PDF]
|
|
|
|
|
|
H. T. Lynch, W. G. Sanger, S. Pirruccello, B. Quinn-Laquer, and D. D. Weisenburger RESPONSE: Re: Familial Multiple Myeloma: a Family Study and Review of the Literature J Natl Cancer Inst, March 20, 2002; 94(6): 463 - 463. [Full Text] [PDF]
|
|